AstraZeneca Won IgAN on a Proteinuria Proxy — but the Category's Price Was Set at $60,000 a Year

The I CAN trial randomized roughly 510 adults across 28 countries 1:1 to intravenous ravulizumab every eight weeks after a loading dose, with weight-based maintenance, over a 106-week blinded period. At week 34 the treated arm showed a 46.6% reduction in 24-hour urine protein creatinine ratio from baseline against 5.6% for placebo — a placebo-adjusted treatment effect of 43.4% (95% CI 33.5%–51.8%, p<0.0001). Separation was visible by week 10, at 36.7% versus 8.5%. The safety profile looked like the established C5 profile: upper respiratory infection 11.3%, nasopharyngitis 9.2%, infusion-related reactions 8.4%.

The label language is where the commercial constraint lives: approved under accelerated approval based on reduction in proteinuria, with continued approval contingent on verification and description of clinical benefit, and it has not been established whether Ultomiris slows kidney function decline.

The IgAN market is no longer a rare-disease market, and it is no longer a complement-only market. Six therapies are approved in the US with a seventh under FDA review, spanning glucocorticoid, dual endothelin/angiotensin, complement factor B, complement factor D, APRIL antibody and terminal C5 blockade. The two most consequential recent approvals are both complement — Fabhalta on a traditional approval with a kidney-function endpoint, and Ultomiris on a surrogate.

But the pricing anchor for this category was not set by complement. ICER's March 2026 final report benchmarked the two B-cell-directed agents, and it is those benchmarks that payers will now reference in contracting. Complement blockade won the label race while the price war is being priced off someone else's cost-effectiveness model — and the population denominators do not even agree, with AstraZeneca citing 217,000+ diagnosed Americans against ICER's prevalence-based eligible pool of 87,932.

The underappreciated event in IgAN is not an approval. It is the price benchmark. In its final report on B-cell-directed therapies for IgAN, ICER set health benefit price benchmarks of $60,000–$81,000 a year for sibeprenlimab and $60,000–$80,000 for atacicept — levels that require discounts of 79% to 85% off list — while Nefecon's course-based pricing of $110,900–$143,000 needed only a 13% to 29% cut. Against an eligible US population of 87,932 patients with 20% starting treatment each year, ICER's budget math is stark: at a $292,500 annual net price, only 6% of eligible patients could be treated before hitting the agency's $821M potential budget-impact threshold. At $64,500 a year, 97% could.

This is the mechanism that will decide the category, and it is the reason a 43.4% proteinuria result does not translate into revenue.

Once price is benchmarked, the differentiator becomes the ability to sell into it. The two companies running the fastest launch efforts in IgAN are the two least able to fund a repriced market: Travere's Filspari did $141.1M of US net product sales in Q2 2026, up 96%, and Vera's Trutakna was cleared in July, yet neither carries a balance sheet built for an 80%-plus discount. Demand is proven; the ability to profit from that demand at benchmarked prices is not — and that is the distinction this clearance exposes.

The same logic runs in reverse for the incumbents. Novartis and Otsuka can price for value because they have scale, and AstraZeneca can discount because Rare Disease generated $4,911M in the first half.

A population-scale launch of a chronic intravenous antibody strains the whole chain, not just the label. AstraZeneca has contracted large-scale biologics capacity externally: Samsung Biologics expanded its supply agreement with the company to approximately $380M from $331M for drug substance and drug product, with Plant 4 taking its capacity to 620,000 litres, the largest biomanufacturing footprint in the world, and WuXi Biologics holds a strategic manufacturing partnership with AstraZeneca for Evusheld in China while scaling planned capacity toward more than 580,000 litres by 2026. Neither disclosure names ravulizumab, and the manufacturer of the IgAN presentation is not disclosed — but a franchise that must supply q8w intravenous dosing for a population of six figures has to draw on exactly this kind of contracted capacity.

Downstream, the economics reverse. ICER's cost offsets — $430,000 per year of deferred kidney failure for sibeprenlimab, $434,000 for atacicept, $225,000 for Nefecon — are the reason payers fund these drugs at all, and they are a transfer of value away from dialysis and transplant. The same disease is creating a pre-dialysis care market that did not exist in 2024.

There is a useful irony in how the IgAN category is being disrupted. The fastest-arriving medicine came from a mechanism discovered long before machine learning existed: Ultomiris is a C5 antibody that has been in AstraZeneca's portfolio through five prior indications. Meanwhile the AI-native and AI-partnered discovery model is producing targets and options rather than approved nephrology products.

The structure of those deals explains why. AstraZeneca's October 2026 collaboration with insitro pays $40M upfront against up to roughly $1.46B in development and commercial milestones plus single-digit royalties, with exclusive worldwide rights to advance programmes AstraZeneca nominates; its expanded arrangements with Tempus AI and Pathos put roughly $200M behind the largest multimodal foundation model in oncology; Novartis expanded its Isomorphic Labs collaboration in February 2025 after a January 2024 deal that carried $37.5M upfront against nearly $3B of potential value. Every one of these transactions buys a target cheaply and leaves the franchise economics, the payer contracts and the launch infrastructure with the incumbent — which is precisely the structure that decides this category.

Near term, nothing about this clearance changes a revenue line, and the market will be trading reimbursement mechanics rather than science. The first checkpoint is AstraZeneca's 9M and Q3 results on Oct 30, 2026, four days after the approval, where Rare Disease and Ultomiris trajectories are the only way to size the IgAN launch ramp.

Over one to three years the sequence is fixed by documents already in the public record: the week-106 eGFR analysis in I CAN, which decides whether Ultomiris keeps its label; the confirmatory data that lift Vera's Trutakna and Otsuka's Voyxact from surrogate to verified benefit; and a possible ICER read on a complement inhibitor, which does not yet exist because the March benchmark covered B-cell-directed agents only.